STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Opinion
4hOpinion
Baylor Genetics Supports Bipartisan House Bill to Broaden Medicaid Access to Genomic Sequencing for Children who Meet Medical Criteria
In 2025, Baylor Genetics was named an official genetic testing partner of the Child Neurology Society.
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...
GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes ...
GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% ...
Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GeneDx (Nasdaq: WGS), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback